The global biological safety testing products and services market size is expected to reach USD 9.30 billion by 2030, registering a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is predominantly driven by the increasing production of biologics, boosting the demand for highly effective biological safety testing tools. The increasing disease burden is expected to be a major factor responsible for the rising production of biologics, thereby propelling the market growth.
The increasing prevalence of chronic diseases associated with lifestyle, including diabetes and cancer, is a key factor contributing to the rise in drug development and subsequent commercialization. This is expected to increase the need for ensuring & scrutinizing the safety of specialized and targeted therapies, evaluating outcomes, and circumventing probable shortcomings. In addition, biotechnology and pharmaceutical companies are increasingly integrating biological safety testing products and services to produce contamination-free and highly potent biologics to cater to the large number of people suffering from target diseases. Safety testing for viral conditions is proving to be one of the primary concerns of most companies as it is a critical component of manufacturing, chemistry, and control of biologics. This is fueling growth opportunities in the market.
Laboratory-based contamination is leading to the development and refinement of workstations by incorporating biological safety products and services. The increasing need to work with tissue cultures, maintain the sterility of cell lines, and minimize cross-contamination has increased concerns regarding product integrity. Rising involvement by government healthcare organizations for implementing good manufacturing practices and subsequent testing & control at every production stage is expected to widen the scope for growth.
Furthermore, key players operating in the biological safety testing product & services market are constantly focusing on developing novel products and technologies, further expanding their product portfolio, and to meet the rising demand for biological safety testing globally. For instance, in December 2022, -Charles River Laboratories International, Inc. announced the launch of Endosafe Nexus 200, a fully robotic instrument capable of processing both complex or undiluted, serial dilutions for water, in-process, and final product testing, further expanding its endotoxin testing portfolio. The incorporation of automation through robotics has enabled streamlining the quality control process and subsequently improving overall process efficiency.
Request a free sample copy or view report summary: Biological Safety Testing Products And Services Market Report
Based on product, the reagents and kits segment held a leading revenue share of over 39.9% in 2023, due to their extensive use in research and clinical laboratories
Based on application, the vaccines & therapeutics segment dominated in terms of market share in 2023 and is anticipated to grow at fastest growth rate owing to the increase in disease outbreaks over the years
Based on test type, the endotoxin tests segment dominated in terms of the market share of in 2023, owing to the rising prevalence of bacterial infections
North America dominated the overall market with a revenue share of 35.13% in 2023, owing to rising research investments in biotechnology and the growing burden of chronic diseases. This anticipates increasing the demand for molecular cytogenetics in the region over the forecast period
Asia Pacific is anticipated to grow at the fastest growth rate over the forecast period due to growing healthcare spending and the development of healthcare infrastructure in developing countries like India and China
Grand View Research has segmented the global biological safety testing products and services market on the basis of product, application, test type, and region:
Biological Safety Testing Products And Services Product Outlook (Revenue, USD Million, 2018 - 2030)
Reagents & Kits
Instruments
Services
Biological Safety Testing Products And Services Application Outlook (Revenue, USD Million, 2018 - 2030)
Vaccines & Therapeutics
Vaccines
Monoclonal Antibodies
Recombinant Protein
Blood & Blood-based Products
Gene Therapy
Tissue & Tissue-based Products
Stem Cell
Biological Safety Testing Products And Services Test Type Outlook (Revenue, USD Million, 2018 - 2030)
Endotoxin Tests
Sterility Tests
Cell Line Authentication & Characterization Tests
Bioburden Tests
Adventitious Agent Detection Tests
Residual Host Contamination Detection Tests
Others
Biological Safety Testing Products And Services Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Biological Safety Testing Products And Services Market
Charles River Laboratories
BSL Bioservice
Merck KGaA
Samsung Biologics
Sartorius AG
Eurofins Scientific
SGS Société Générale de Surveillance SA
Thermo Fisher Scientific Inc.
BIOMÉRIEUX
Lonza
"The quality of research they have done for us has been excellent..."